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Abstract
Background: A limitation with current imaging strategies of recurrent glioma undergoing radiotherapy is that tumor and
radiation injury cannot be differentiated with post contrast CT or MRI, or with PET or other more complex parametric
analyses of MRI data. We propose to address the imaging limitation building on emerging evidence indicating that effective
therapy for recurrent glioma can be attained by sensitized T-cells following vaccination of primed dendritic cells (DCs). The
purpose of this study was to determine whether cord blood T-cells can be sensitized against glioma cells (U-251) and if
these sensitized cytotoxic T-cells (CTLs) can be used as cellular magnetic resonance imaging probes to identify and
differentiate glioma from radiation necrosis in rodent models.
Methodology/Principal Findings: Cord blood T and CD14+ cells were collected. Isolated CD14+ cells were then converted
to dendritic cells (DCs), primed with glioma cell lysate and used to sensitize T-cells. Phenotypical expression of the
generated DCs were analyzed to determine the expression level of CD14, CD86, CD83 and HLA-DR. Cells positive for CD25,
CD4, CD8 were determined in generated CTLs. Specificity of cytotoxicity of the generated CTLs was also determined by
lactate dehydrogenase (LDH) release assay. Secondary proliferation capacity of magnetically labeled and unlabeled CTLs
was also determined. Generated CTLs were magnetically labeled and intravenously injected into glioma bearing animals
that underwent MRI on days 3 and 7 post- injection. CTLs were also administered to animals with focal radiation injury to
determine whether these CTLs accumulated non-specifically to the injury sites. Multi-echo T2- and T2*-weighted images
were acquired and R2 and R2* maps created. Our method produced functional, sensitized CTLs that specifically induced
U251 cell death in vitro. Both labeled and unlabeled CTLs proliferated equally after the secondary stimulation. There were
significantly higher CD25 positive cells (p=,0.006) in CTLs. In addition, T2- and T2*-weighted MR images showed increased
low signal intensity areas in animals that received labeled CTLs as compared to the images from animals that received
control cells. Histological analysis confirmed the presence of iron positive cells in sites corresponding to MRI low signal
intensity regions. Significant differences (p=,0.001) in tumor R2 and R2* values were observed among the groups of
animals. Animals with radiation injury exhibited neither MRI hypointense areas nor presence of iron positive cells.
Conclusion: Our results indicate that T-cells can be effectively sensitized by in vitro methods and used as cellular probes to
identify and differentiate glioma from radiation necrosis.
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Introduction
Malignant glioma is one of the most aggressive tumors with a
poor prognosis despite the available treatments [1]. Standard
treatment procedures, consisting of surgery and radiation therapy
(followed by adjuvant chemotherapy), very often fail due to the
inability to accurately delineate tumor margins [2–4], and the
median survival time for patients with recurrent glioblastoma
multiforme (GBM) is less than 1 year [5]. The infiltrative nature of
GBM is considered to be one of the main factors impeding the
complete removal of tumor mass by surgical procedure [6].
Following radiation therapy or surgery, recurrence is common
and almost invariably occurs within ,2 cm of the prior resection
line. Detection of recurring tumor at an early stage using current in
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9365vivo imaging techniques is difficult, mainly due to normal tissue
damage that occurs following radiation or surgery [7,8]. Hentschel
and Sawaya emphasized the need for high quality imaging to detect
recurring tumors, indicating that residual or satellite tumor cells
have a potential of becoming even more aggressive and resistant to
therapy, as compared to the original primary tumor [6].
Unlike the surrounding normal cerebral vasculature, tumor
vessels are typically more permeable to contrast agents and can
thus be detected by contrast-enhanced magnetic resonance
imaging (MRI) or computed tomography (CT). However, areas
of radiation injury can also show enhancement due to active
inflammation accompanied by an increase in vascular permeabil-
ity. Differentiating recurrent glioma from radiation injury based
only on changes in vascular permeability and/or blood volume
based on contrast enhanced MRI or CT is problematic. MR
spectroscopy (MRS), diffusion weighted imaging (DWI) and
mapping of the apparent diffusion coefficient (ADC) have
produced mixed results in differentiating recurrent tumor from
radiation injury [9,10]. It has been reported that MRS and ADC
values, alone or combined, are not conclusive in discriminating
between tumor recurrence and radiation injury when an
admixture of microscopic tumor and necrotic tissues are present
in the brain [9]. In addition, localization of observed MRS
changes requires co-registration of MRS data with yet another
high resolution MRI.
Nuclear medicine imaging techniques such as
18F-FDG positron
emission tomography (PET) and single photon emission computer-
ized tomography (SPECT) have been used to differentiate recurrent
glioma from radiation injury; however, the results have been
controversial and inconclusive [11,12]. PET and SPECT have
limited spatial resolution and relatively high cortical background
activity, therefore,
18F-FDG-PET cannot accurately delineate
residual tumor after therapy [13,14]. Moreover,
18F-FDG-PET
images also need co-registration with MRI or CT images to
differentiate small or suspicious lesions. In contrast,
11C-MET-PET
is better suited for monitoring the effects of radiation therapy where
injury is displayed as a reduction of the relative methionine-uptake.
Nonetheless, the short half-life of
11C is still considered a significant
limitation to the widespread use of this technique [14].
Tumor immunology has long been a focus of cell-based vaccine
therapy research. Dendritic, as well as T-cells, are considered to be
the best candidates for developing cellular therapies to treat
malignancies. Dendritic cell-based vaccination therapy against
recurrent glioma that utilizes the patient’s own dendritic cells that
are pulsed, ex-vivo, with the derived glioma cell-lysate is currently in
clinical trials [15,16]. In experimental glioma models, an increase
in the number of cytotoxic T-lymphocytes (CTL) compared to
control or pre-vaccination levels is observed following the
administration of glioma cell-lysate-pulsed dendritic cell therapy.
Previous studies by our group have demonstrated initiation of
cellular immunity in adoptive transfer model in syngeneic Fisher
rats [17]. It has been hypothesized that using a well-established
glioma lysate-pulsed dendritic cell technique, sensitized T-cells (i.e.
CTLs) can be developed in vitro. These CTLs can be magnetically
labeled and serve as cellular probes that can be tracked in vivo by
cellular magnetic resonance imaging (CMRI), to detect and
differentiate human glioma from radiation injury.
Recently, we have created superparamagnetic iron oxide
(SPIO)-transfection agent complexes for labeling mammalian cells
using two FDA approved agents (ferumoxides and protamine
sulfate) [18–20]. Cells labeled with the ferumoxides-protamine
sulfate (FePro) complex can be imaged at clinically relevant MRI
field strengths using standard imaging techniques, and at the
higher fields commonly used for animal experiments. Results from
our group and other investigators demonstrated that MRI can
track and monitor the migration of magnetically labeled cells in a
variety of organs and disease models [21–25]. Investigations by
our group and other laboratories demonstrate that labeling various
types of cells with ferumoxides does not alter the viability and
functional capability of these cells, or the differentiation capacity of
stem cells [26,27]. For example, after secondary stimulation with
proteolipid protein (PLP), labeled sensitized T-cells exhibited
proliferation capacity similar to that of control, non-labeled cells
[22]. In summary, cellular MRI acquires high spatial resolution
images to detect the accumulation of small numbers of
magnetically labeled cells [18,21–23]. This technique may enable
the delineation of tumor margins from surrounding tissues in a
more precise manner. In addition, identification and precise
localization of in vivo accumulated cells does not require the
combining or registration of additional scans.
The purpose of this study was to determine whether: (1) T-cells
collected from cord blood can be sensitized against glioma cells, (2)
CTLs can be labeled effectively using ferumoxides-protamine
sulfate (FePro) complexes for CMRI, (3) labeled CTLs can be used
as probes to identify implanted glioma in a rodent model by
CMRI, and whether (4) labeled CTLs can be used to differentiate
glioma from radiation necrosis.
Results
Production of Mature DC and CTLs Specific for U-251
Tumor Cells
To generate immature and mature DCs, CD14+ cells were
isolated from cord blood and first incubated for 4 days in
immature DC media that contained GCSF and IL-4. After 4 days
of incubation this media, expression of CD14 was down-regulated
from 100% to 0.06%, whereas the expression of CD86 immature
DC marker was up-regulated (from 56.95613.82 to
77.9563.59%). On the other hand, the level of CD83 mature
DC marker remained low (1.8061.23%) (Supplemental mate-
rial, Table S1). At day 5, U-251 tumor cell lysate was added to
the generated immature DCs and by day 6, cell started exhibiting
morphological changes that were accompanied with the further
changes in the expression of DCs’ phenotypical markers such as
CD83, CD86, HLA-DR (Figure 1, Supplemental material,
Table S1). After the addition of TNF-a, that induced DC
maturation, an up-regulation of immature CD86 marker (from
77.9563.59% to 93.4465.58%) and mature CD83 marker (from
1.8061.23% to 55.8063.80%) was observed. Upon maturation,
DCs were irradiated and used to sensitize the T-cells. (Supple-
mental material, Table S1 shows the effect of different doses of
cytokines on the expression of CD 14, CD 86, CD 83 and HLA-
DR in CD14 derived DCs). Incubation of mature, tumor primed,
irradiated DCs with cord blood derived T-cells induced immuno-
logical T cell sensitization that resulted in generating CTLs specific
for U-251 tumor cells. Figure 2 shows the morphological as well
as the phenotypical changes that were observed through the
process of sensitization of T-cells to CTLs, as detected by flow
cytometric analysis. T-cells that were co-cultured with irradiated,
primed, mature DCs, exhibited higher numbers, as well as the
morphological changes such as elongation and increase in size, as
compared to control cells. Proliferation assay (MTT, (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetra-
zole) assay) indicated a significant increase in the number of cells
that were co-cultured with irradiated primed DCs, as compared to
control T cells cultured alone. The optical density (OD) values
determined by MTT assay of co-cultured cells were significantly
higher (p=,0.05) than combined values of T-cells and irradiated
CTLs as Cellular MRI Probes
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Figure S1). Flow cytometry detected an increase in the numbers
of CD4+, CD8+ and CD25+ (activated T-cells) cells following
sensitization, as compared to control T-cells (Figure 2). However,
significant difference was observed only with CD25 cells
(4.5764.92% vs 31.7260.13%, p=,0.006).
Next, we determined whether generated CTLs can be labeled
effectively using ferumoxides-protamine sulfate (FePro) complexes
for CMRI. After 4 h of CTLs incubation with FePro, more than
90% of CTLs were labeled, with the average intracellular iron
content of 4.960.061 pg/cell. Unlabeled CTLs had an average
iron content of 0.11360.051 pg/cell (p=,0.001). There were no
significant differences (p=.0.05) between the labeled and
unlabeled CTLs with respect to the viability (55% for unlabeled
CTLs and 53% for labeled CTLs) and secondary proliferation
capacity when secondarily co-cultured with irradiated primed DCs
(OD=0.266.003 for unlabeled CTLs and OD=0.2796.015 for
labeled CTLs). (Supplement Figure S2 shows Prussian blue
staining of labeled and unlabeled CTLs).
Specificity of CTLs was demonstrated by the 8 fold increase in
the number of dead cells in U-251 tumor cells co-cultured with
CTLs, compared to that in U-251 tumor cells cultured alone
(data not shown). Figure 3A shows the morphological changes at
0 and 18 hours of CTL/U-251 cell co-culture and the
accumulation of either unlabeled CTLs or labeled CTLs around
U251 cells. These changes were not seen when U251 cells were
co-cultured with control T-cells. Similar patterns of cell
accumulation were observed for both FePro labeled and
unlabeled CTLs. U251 cell specific accumulation of CTLs was
more prominent in wells that contained 200k of CTLs
(Supplement Figure S3 show CTLs’ effect on other glioma cells
lines). In addition, significantly (P=,0.035) higher concentra-
tions of LDH were detected in the supernatant of U251 cells co-
cultured with CTLs sensitized to U251 compared to that of the
supernatant of MBA-MD-231 cells co-cultured with the same
CTLs sensitized to U251. These data strongly indicate the
immunological specificity of the produced CTLs for U-251 cells
(Figure 3B). There was increased number of magnetically
Figure 1. Making of mature dendritic cells from CD14+ cells. Upper panel: Morphological changes in CD14+ cells following the addition of
immature and mature dendritic cell (DC) media. Cells were grown in RPMI-1640 media containing 10% FBS, IL4 and GCSF; at day 8 TNF-a was also
added. CD14+ cell morphology changed from the rounded cells to the cells exhibiting short dendrite-like processes. Mature DC attached to the
growth surface. Lower panel: Multicolor flow cytometric dot plots of CD14+ cells-derived mature DCs at day 11 (3 days after adding TNF-a) indicate
down regulation of CD14 and up regulation of CD86, CD83 and HLA-DR after DCs maturation.
doi:10.1371/journal.pone.0009365.g001
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that of breast cancers. The labeled CTLs accumulated not only at
the periphery but also in deeper parts of the glioma. Similar
accumulation was not observed in breast cancer, which indicates
in vivo specificity of generated CTLs (supplement material,
Figure S4 (S4A, S4B)).
MR Images, Relaxation Maps and Histology –Animal
Tumor Model
T2- and T2*-weighted images (T2WI and T2*WI, respectively)
detected growing tumors in the brains of all the animals. Low
signal intensity (hypointense) areas were seen near the scalp and
within the center of the tumors only in a few animals
corresponding to areas of hemorrhage attributed to the tumor
cell implantation procedure (i.e. needle track). Corresponding R2
(1/T2) and R2* (1/T2*) maps show high signal intensity areas at
the corresponding sites that were different from the high signal
intensity seen due to accumulation of Prussian blue positive cells
around the periphery of the tumors, (see below). None of the
tumors that received unlabeled CTLs showed hypointense regions
on T2WI and T2*WI around the tumors, however no Prussian
blue positive cells were seen in or around the tumors on
histological exams (Figure 4A, upper panel). In comparison,
animals that received FePro labeled CTLs demonstrated hypoin-
tense voxels on T2WI and T2*WI around the tumors, as well as in
the central part of the tumors. The hypointense regions were more
pronounced on T2*WI and were clearly visible as hyperintense
areas on the corresponding R2* maps (Figure 4A, lower panel).
Prussian blue staining showed multiple, iron positive cells within
both, the periphery and the tumors. Hypointense voxels were
present on T2*WI obtained on days 3 and 7. Animals that
received labeled control T-cells also demonstrated hypointense
voxels on T2*WI and corresponding, increased R2* values
(Figure 4A, middle panel). However, the hypointense regions
Figure 2. Morphological and phenotypical changes in T-cells during sensitization. Upper panel: Culture of cord blood derived T-cells in
the absence (left) or presence (right) of U251 cell lysate primed irradiated DC (PIDC). T-cells were cultured in RPMI-1640 media containing 10% FBS
and IL-2 for 6 days. Note the number and morphology of the sensitized T-cells (right). Middle panel: Dot plot analysis of flow cytometric data of the
CTLs showing activated T-cells (CD25) that are also both CD4 and CD8 positive. Lower panel: Flow-cytometric analysis (histogram plot) of T-cells
cultured in the absence (red line) and presence (black line) of PIDC for day 6. Note the higher number of CD4+, CD8+ and CD25+ T-cells on day 6.
There were a significantly (p=0.006) higher number of activated T-cells on day 6 in the presence of PIDC.
doi:10.1371/journal.pone.0009365.g002
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magnetically labeled CTLs. Figure 4B shows detailed histological
analysis of the tumor that received LCTL. Immunohistochemistry
confirmed the accumulation of activated human T-cells
(CD45RO) at the sites of Prussian blue positive cells (Figure 5)
in animals that received FePro labeled CTLs. CD45RO positive
cells were also seen in tumor that received unlabeled CTLs.
(Supplement materials, Figure S5 (S5A and S5B) also show
Figure 3. Specificity of labeled and unlabeled cytotoxic T-cells (LCTLs and ULCTLs, respectively) in vitro.F i g u r e3 A :U251 cells
(100k) were plated in 24-well plates and grown until 90% confluent. Then unlabeled control T-cells (ULCTCs), LCTLs or ULCTLs were added to
the cultures (100k and 200k per well). The migration and specific accumulation of T-cells around the tumor cells were microphotographed at
0h and 18h of co-culture. Left column: Morphology of U251 alone and after incubation with 200k of CTC at 0 and 18 hours. There is no
change in the morphology of U251 and CTC seems to be sitting on the tumor cells even after 18 hours of incubation. Middle column:
Morphology of U251 cells at 0 and 18 hours after incubation with ULCTL. The ULCTLs seem to be sitting on the tumor cells at 0 hour. The
specific accumulation of ULCTLs around the tumor cells (arrows) was seen after 18 hours for both 100k and 200k ULCTLs conditions. Compared
to the morphology of U251 cells at 0 hour, the dramatic changes in the morphology of U251 cells were observed. Cells become elongated and
sparse. This phenomena was more pronounced at higher density (i.e. 200k) of ULCTLs. Right column: Similar to ULCTLs, LCTLs also show
similar phenomena of specific accumulation around the tumor cells (arrows) and changes in the morphology of U251 cells. Figure 3B: Both
U251 (100k) and human breast cancer cells (MBA-MD-231, 100k) were incubated in their respective media (1 ml in 24-well plate) in the
presence or absence of 200k CTLs overnight. On the next day, supernatants from all the conditions were collected and the lactate
dehydrogenase (LDH) contents were determined. Average fluorescent values detected in the supernatant of U251 and MBA-MD-231 cultures
without CTLs were deducted from the fluorescent values detected in the corresponding cell lines in the presence of CTLs. The data are
expressed as mean 6 SEM. Significantly higher (p=,0.017) LDH activity was observed in U251 culture in the presence of CTLs indicating
specificity of the sensitized T-cells.
doi:10.1371/journal.pone.0009365.g003
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smaller tumor).
MR Imaging and Histology- Animal Model of Brain
Radiation Injury
T2WI and T2*WI obtained 8 weeks after irradiation did not
show any changes in signal intensity at the sites of radiation injury,
as compared to the control, healthy hemispheres. There were no
signal intensity changes following intravenous administration of
magnetically labeled cells, despite the obvious radiation injury as
determined by histological analysis (Luxol fast blue and FITC-
labeled tomato lectin staining). Luxol fast blue staining showed
extensive loss of myelination at the sites of radiation exposure and
lectin staining at the corresponding sites showed dilated blood
vessels indicating vascular injury. There were no Prussian blue
Figure 4. MRI and Prussian blue positive cells in tumors. Figure 4A: T2-weighted and T2*-weighted images and their corresponding R2 and R2*
maps and DAB enhanced Prussian blue staining from representative animals that received unlabeled CTL (ULCTL, upper row), labeled control T-cells (LCTC,
middlerow)andCTL(LCTL,lowerrow).BothT2WandT2*Wimagesshowwellestablishedtumorsinthebrain,however,lowsignalintensityareaswereonly
seen in tumors that received LCTC and LCTL. Corresponding R2* maps show high signal intensity areas. Animals that received LCTL show high signal
intensityareas bothat the peripheral and central part ofthe tumors (arrows).CorrespondingDAB enhanced Prussian blues staining show multiple Prussian
blue positive cells in tumors that received LCTL (arrows). There are a few Prussian blue positive cells seen in tumor that received LCTC (arrow). No definite
PrussianbluepositivecellswereseenintumorthatreceivedULCTL.AreasofnecrosiscaneasilybeidentifiedbycomparingT2WIandR2maps(thickarrows)
in tumor that received LCTL (lower row). Bars on the images measure 100 mm. Figure 4B: Detailed histological analysis of the tumor that received LCTL.
Bars on the images measure 100 mm. Upper panel: T2-weighted image (T2WI) and T2*-weighted image (T2*WI) show areas of necrosis (high signal
intensity on T2WI and T2*WI and low signal intensity on R2* map). Thin arrows show the sites of necrosis and thick arrows show possible site of
accumulated iron positive cells. Middle panel: Representative histological section with similar tumor orientation (within the constraints of the
experimental limitations, i.e. 1 mm thick MRI slices versus 10 m thick histological section) show central necrosis (N) in the tumor with areas of iron positive
cells (black arrows) seen in the central and peripheral part of the tumor that received iron labeled CTLs. Lower panel: Enlarged view of the boxed areas.
doi:10.1371/journal.pone.0009365.g004
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radiation injury (Figure 6). MR Image analysis demonstrated
that, when normalized to the contralateral hemispheres, both R2
and R2* values in tumors of the animals that received labeled
CTLs were significantly higher (p=,0.001) compared to that of
the animals that received control T-cells and unlabeled CTLs
(Figure 7). The significant changes were observed at both, day 3
and day 7 after the administration of the cells. On the other hand,
there were no significant differences in R2 and R2* values seen in
the irradiated hemispheres of the animals that received either
labeled or unlabeled CTLs.
Discussion
The results of this ‘‘proof of principle’’ study demonstrate that
incubation of irradiated mature DCs that were primed with U251
tumor cell lysate with T cells can generate fully functional
cytotoxic T-cells (CTLs) against human glioma U251 cell line. In
addition, produced CTLs can be magnetically labeled and used as
cellular MRI probes for delineating sites of the implanted tumors.
The results supported our hypothesis that these magnetically
labeled CTLs would not accumulate at the sites of radiation injury
and could be used to differentiate glioma from radiation injury by
cellular MRI. To our knowledge, this is the first study to utilize
established methods to produce CTLs in vitro that are targeted
against a human glioma cell line (U251). In addition, this is the
first study to use these sensitized CTLs in conjunction with in vivo
MRI methods to differentiate implanted tumors from radiation
injury in the rat brain. Investigators have used T-cells to target
tumors in various experimental and clinical settings [28–33]. In
another animal model of glioblastoma (U87 cells), investigators
have shown the effectiveness of genetically modified T-cells to
reduce tumor mass and demonstrated corresponding changes on in
vivo MRI [31]. Using the same genetically altered T-cells,
Yaghoubi et al. have shown the migration and accumulation of
CTLs to tumor by PET scanning in a patient with glioblastoma
[30]. Rosenberg et al. have shown mild to moderate responses to
genetically altered CTL treatment in melanoma patients [32,34].
In the previous studies, CTLs were collected either from animals
(in vivo sensitization) or expanded ex vivo by genetic manipulation of
T-cells to target tumor specific antigens. In our previous study, we
used cellular MRI to demonstrate that FePro labeled sensitized
splenocytes (containing CTLs and other cells) localized at sites of
tumor [17]. The T2WI and T2*WI and the histochemistry
demonstrated the presence of Prussian blue positive cells in and
around the sites of implanted tumors. In the current study, the
accumulation and distribution of magnetically labeled CTLs to the
implanted glioma were similar to our previous report [17] and the
CTLs were identified not only in the periphery but also within the
tumor, as confirmed histologically by the presence of CD45RO
positive cells.
Although vaccines against most tumors are under development,
dendritic cell-based vaccines have only been used in early clinical
trials for glioblastoma multiforme, with varying degrees of success
[15,16]. The basic treatment principle behind these dendritic cell-
based vaccines studies was to initiate sensitization of endogenous
T-cells by injecting primed dendritic cells, subcutaneously, that
would in turn migrate to the nearest draining lymph nodes and
sensitize T-cells against the antigen. The sensitized (cytotoxic) T-
cells would then target cells that express the antigens, resulting in
tumor cell death [35–37]. Most of the dendritic cell-based
vaccinations were based on priming dendritic cells with the
specific tumor antigen. In the current study, we used U251 whole
cell lysate, where the specific tumor antigen/s responsible for the
sensitization was unknown, to prime the dendritic cells for in vitro
sensitization of T-cells. However, LDH release studies demon-
strated the specificity of the produced CTLs against U251 cells.
Figure 5. MRI and activated T-cells in tumors. Representative cases of animals that received labeled CTL (A-C) and unlabeled CTL (D-F). (A) T2*-
weighted images (T2*WI) showed low signal intensity areas all over the tumors (both periphery and center). (B) DAB enhanced Prussian blue staining
showed multiple Prussian blue positive cells corresponding to boxed area (brown spots). (C) Multiple CD45RO positive cells (arrows, activated T-cells)
were seen at the corresponding area. (D) T2*WI showed well developed tumor with areas of low signal intensity at the periphery. There were no
Prussian blue positive cells seen at the corresponding areas (E), however, multiple hemorrhagic areas were observed (arrow on E). (F) Multiple
CD45RO positive cells seen in the tumor. Scale bar =100 mm.
doi:10.1371/journal.pone.0009365.g005
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molecular imaging probes to delineate implanted tumors by MRI.
The recently developed rapid one step (i.e., ,4 hr) ferumoxides-
protamine sulfate method was used to label the CTLs and
generate an effective cellular probe compatible with MRI [38].
Animals that received magnetically labeled control T-cells
(LCTC) showed smaller numbers of Prussian blue positive cells in
the tumors than those that were given LCTLs. However, analysis
of R2* values did not show any significant differences from that of
the animals that received unlabeled CTLs (ULCTL). On the other
hand, the animals that received LCTLs showed large numbers of
Prussian blue positive cells and significantly higher R2* values in
the tumors. These results indicated that CTLs targeted and
accumulated within the tumors as a necessary first step in the
development of this approach as a cellular therapy. There was no
difference in the distribution of CD45RO positive cells in the
tumor in the animals that received LCTL versus ULCTL. These
findings indicate that labeling the CTLs with superparamagnetic
iron oxides nanoparticles did not alter their ability to home or
target the tumors. Moreover, there was no difference in the
migration and accumulation specificity between LCTL and
ULCTC as shown in our in vitro experiments. These results
support previous studies demonstrating that magnetic labeling
does not alter cell function [27]. The accumulation of magnetically
labeled control T-cells to the tumors can be explained in two ways:
1) non-specific accumulation or 2) due to sensitization of the
administered labeled control T-cells to tumor antigens (from
implanted tumors) during their passage through the spleen.
Although the nude rats were used in this study, this kind of
migration and priming of the dendritic cells cannot be ruled out.
PET images have high contrast to noise level but are limited by
its lower spatial resolution as compared to other tomographic
imaging techniques. Genetically altered cytotoxic T-cells have
recently been used in the glioblastoma patients where the
migration and accumulation of these cells was tracked using
PET [30]. However, it is necessary to register the PET to MR
images in order to delineate the anatomical sites of the
accumulated radiotracer activity. If magnetically labeled cells are
used as cellular probes in combination with higher field strength
MRI systems with higher spatial resolution, more sophisticated
data acquisition approaches and more robust image analysis
[39,40], it would be possible to translate this approach to the
bedside for the clinical evaluation of glioblastoma patients.
Investigators have already used magnetically labeled cells in a
different clinical setting to target the migration of dendritic cells,
neural stem cells, bone marrow derived CD34+ cells and islet
grafts [41–44]. Despite the advancement in imaging modalities,
the early detection of residual tumor or metastatic foci in
Figure 6. MRI and histology in radiation injury. Representative magnetic resonance imaging and corresponding histochemical analysis of
radiation injured (8 weeks after 50Gy focal irradiation) animal that received labeled CTL. (A) T2*-weighted image showed no definite low signal
intensity area at the site of radiation injury (arrow) compared to contralateral hemisphere. (B) Corresponding R2* map also showed no high signal
intensity area. Luxol fast blue staining revealed extensive loss of myelination at the site of radiation injury (C) compared to that at the corresponding
site of contralateral normal hemisphere (D). FITC-tagged tomato lectin staining showed loss of normal blood vessels morphology with evidence of
dilatation (arrows) at the corresponding site of radiation injury (demyelinated area) (E), in contrast to the vessel distribution seen in the corresponding
site of the contralateral normal hemisphere (F). DAB enhanced Prussian blue staining showed no Prussian blue positive cells at the corresponding
radiation injured or contralateral normal hemispheres (G and H). Luxol fast blue, lectin and Prussian blue stained tissues sections were obtained from
consecutive slices.
doi:10.1371/journal.pone.0009365.g006
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the areas with a mixture of inflammation and malignancy
[9,10,45,46]. Since magnetic labeling of cells does not interfere
with radionuclide or PET tracer accumulation in genetically
engineered cells [47], it will be possible to combine these two
approaches to clinically monitor and functionally assess the
temporal and spatial migration of cells using the recently
introduced PET/MRI systems [48].
Limitations of the Study
We have used whole tumor cell lysate to prime the dendritic
cells, which is a crude and nonspecific approach for sensitizing
DC. Investigators have shown effective sensitization of T-cells with
profound antitumor effects when CD40 ligand (CD40L) is
expressed in tumor cells [49]. Expression of CD40L also helped
maturation of dendritic cells. Although expression of CD40 ligand
was not analyzed in U251 cells, the presence of this ligand cannot
be ruled out. However, our method can be used to prime dendritic
cells with any cancer antigen coming from any type of cancer cells.
In addition, dendritic cells can be genetically modified to express
the specific antigen for sensitization of T-cells. Then, generated
sensitized T-cells can be magnetically labeled and used as a probe
to target the tumor sites.
Current MR imaging strategies do not allow conclusive
determination or differentiation of recurrent or residual glioma
from radiation necrosis. Our new proposed method of determining
recurrent or residual glioma using magnetically label CTLs may
suffer from artifacts due to pre-existing hemorrhage, necrosis and
heterogeneity of vascular changes. Of course these artifacts can be
circumvented by obtaining an MRI prior to injection of
magnetically labeled CTLs and performing image registration
followed by subtracting or comparing the pre from post injection
images (3 and 7 days following injection) assuming the sites of
hemorrhagic and or necrotic foci or pre existing low signal
intensity areas will not change dramatically over the time-frame.
Materials and Methods
Ethics Statement
All animal experiments were performed according to NIH
guideline and the protocol was approved by institutional animal
care and user committee (IACUC). The collection of human cord
blood, separation of cells and using them in the animal studies
were approved by Henry Ford Hospital Institutional Review
Board (Protocol # 3287, 4586). The collection process was
anonymous (without recording any patient’s profile). Written
informed consent was obtained to collect the cord blood and the
consent process was maintained under IRB-approved security
protocol using the IRB-approved consent form.
Human Glioma U251 Cells
Human glioma cells (U251, a generous gift from Dr. Tom
Mikkelsen, Henry Ford Hospital) were grown in Dulbecco’s
modified eagles medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) in 5% CO2/95% air at 37uC in a humidified
incubator. For implantation in rat brain, cells were harvested and
resuspended at a concentration of 8610
7 per ml of serum free
media; 5 ml of the cell suspension was implanted into the rat brain.
Tumor cells were also harvested for generating the whole cell
lysates (see below).
CD14+ and CD2+/CD3+ Cells
Both types of cells were isolated from human cord blood under
the approved IRB protocol. CD14+ positive cells were separated
Figure 7. Relaxation parameters in tumors and radiation injuries. (A) Analyses of R2* values normalized to contralateral normal hemisphere
(indirect indicator of the accumulation of iron positive cells) showed significantly higher (P=,0.001) accumulation of iron positive cells in tumor that
received labeled CTLs. The number of accumulated cells was higher at both, days 3 and 7. n represents the number of sections containing tumors in
at least 5 animals. (B) Similar analyses of R2* values normalized to contralateral normal hemisphere showed no difference between the groups of
animals that received labeled and unlabeled CTLs. n represents the number of sections included in the analyses from 6 animals (5 sections from each
animal, at the level of bregma, 2 sections front and 2 sections behind).
doi:10.1371/journal.pone.0009365.g007
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obtained using a Ficoll gradient separation technique) by magnet
activated cell sorter (MACS) using magnetic beads conjugated
with anti-CD14 antibodies. CD14 depleted cells were further
incubated with anti-CD2 antibodies conjugated to magnetic beads
to separate CD2+/CD3+ cells. Collected CD14+ cells were
further differentiated into dendritic cells. However, based on the
need of the experiments CD2+/CD3+ cells were either cryopre-
served or used immediately. For sensitization of collected T-cells
using mature primed DCs, cells collected from same donor were
used. There was no variability observed from donor to donor with
respect to mature DCs production and sensitization of T-cells.
Preparation of Tumor Cell Lysate
U251 human glioma cells were harvested and washed twice in
ice cold sterile H2O. The cell pellets (1610
8) were repeatedly
frozen in liquid nitrogen and thawed at 37uC to disintegrate the
cells. Cell lysates were resuspended in 5 ml of sterile H2O,
centrifuged at 4uC for 15 min using high speed, and the
supernatant was collected and passed through a 0.45 mm filter.
Total amount of protein in the collected fluid was determined by
standard colorimetric methods using a commercially available
protein concentration assay kit (Pierce, Rockford, IL).
Preparation of Tumor Cell Lysate-Pulsed Mature
Dendritic Cells
CD14+ cells were resuspended at the concentration of
325610
5 cell/ml in RPMI 1640 media containing 10% FBS,
25 ng/ml of IL-4, 50 ng/ml of G-CSF (granulocyte colony-
stimulating factor) and incubated in 5% CO2/95% air at 37uCi n
a humidified incubator for 4 days to make immature dendritic
cells. During this incubation period 1/2 of the media was replaced
with 2/3
rd of fresh media containing cytokines on day 3. On day 5,
suspended and loosely adherent cells were collected, centrifuged
and resuspended in fresh RPMI 1640 media containing 10% FBS,
25 ng/ml of IL-4, 50 ng/ml of GM-CSF and 50 mg/ml of tumor
cell lysate at 5610
5 cells/ml. The cells were thoroughly mixed and
further incubated for 4 days. At the end of the 4 day priming, cells
were collected and resuspended in fresh media containing 10%
FBS, 25 ng/ml of IL-4, 50 ng/ml of GM-CSF and 100 ng/ml of
TNF-a and incubated for additional 4 days. Total incubation time
from the collection of CD14+ cell to generating primed mature
dentritic cells was 12 days. Expression markers specific for
dendritic cells (such as CD14, CD86, CD83 and HLA-DR) were
assessed by flow cytometry before and after addition of TNF- a.
Sensitization of Isolated T-Cells
Either fresh or cryopreserved T-cells tha were isolated from
cord blood were cultured overnight in RPMI 1640 media
containing 10% FBS, sodium pyruvate, non-essential amino acids,
L-glutamine and 10 ng/ml of IL-2 and then co-cultured with
irradiated (35Gy) cell lysate-pulsed mature dendritic cells for 6–7
days. The initial ratio of T-cell to dendritic cell was 10:1. T-cell
proliferation was monitored every day and based on the cell
density, fresh media was added to the co-culture. T-cell
proliferation was determined by a proliferative activity assay
(MTT, (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, a tetrazole) assay) on days 1, 3 and 5 and the values were
normalized using the corresponding control cells. After incubation
for 6 days the T-cells were collected, washed and resuspended in
serum free media at a concentration of 4610
6 cells/ml and labeled
with iron oxides. Phenotypical expression of different T-cell
markers (CD3, CD4, CD8, and CD25) was determined by a flow
cytometer (LSR II, BD Bioscience) before and after sensitization,
as well as after the magnetic labeling of CTLs. Viability and
secondary proliferation (MTT) capacity of magnetically labeled
and unlabeled CTLs were also determined.
Preparation of Ferumoxides-Protamine Sulfate (FePro)
Complex and Labeling of Cells
Commercially available, FDA-approved super paramagnetic
iron oxides (SPIO) ferumoxides suspension (Feridex IV H, Bayer-
Schering Pharmaceuticals Inc, Wayne, New Jersey) contains
particles that are approximately 80–150 nm in size and has a
total iron content of 11.2 mg/ml (11.2 mg/ml of iron). Protamine
sulfate (American Pharmaceuticals Partner Inc. Schaumburg, IL),
supplied at 10 mg/ml, was prepared as a fresh stock solution of
1 mg/ml in distilled water at the time of use. We have labeled
CTLs using a modified published method (also described in
supplement), where instead of making FePro complexes prior to
adding to the cell suspension, we now add ferumoxides (100 mg/
ml) directly to the cell suspension in serum free media and then
add protamine sulfate (3 mg/ml) [38]. The FePro complexes are
formed in the cell suspension. After 15 minutes of incubation in
serum free media, an equal volume of complete media (containing
serum) was added to the cell suspension and further incubated for
4 hours. The cells were then collected, washed with sterile PBS
and resuspended at the specific concentration for injection.
Cellular Viability, Phenotypic Analysis, Labeling Efficiency
and Mean Iron Concentration of FePro Labeled Cells
After labeling, the cells were washed two times with sterile
phosphate buffered saline (PBS) and resuspended in PBS at a
concentration of 3610
7 cells/ml. Cell viability was determined by
trypan blue exclusion assay. Expression markers specific for CTLs
were analyzed by flow cytometer in labeled and unlabeled cells,
using fluorescently conjugated antibodies. Labeling efficiency was
determined by Prussian blue staining and intracellular iron content
that was determined by our published method [50]. Iron
concentration was expressed as average picogram of iron/cell.
Determination of Specificity of Labeled and Unlabeled
CTLs
To determine whether produced CTLs have the specificity to
target U251 cells in vitro and to determine whether FePro labeling
alters this specificity, 100k of U251 cells were plated in 24 well
plates and cultured until reaching 90% confluence. Then, either
100k or 200k of control T-cells, unlabeled CTLs or labeled CLTs
were added separately to the wells containing U251 cells. The
interaction (accumulation of the added T-cells around U251 cells)
of the added cells with U-251 cells was photomicrographed at 0
and 18 hours of co-culture. Both unlabeled and labeled CTLs
were also subjected to secondary stimulation by incubating with
irradiated primed dendritic cells and cell proliferation was
determined as described above.
To determine the cytotoxic specificity of the produced CTLs to
U251 cells, 200k CTLs (sensitized to U251 cell lysate) were co-
cultured overnight with U251 (100k) or human breast cancer cell
(MBA-MD-231, 100k) and the released lactate dehydrogenase
(LDH) was determined by a commercially available membrane
integrity assay kit (Cyto Tox-ONE, Promega corp, WI). LDH
levels indicate cytotoxicity since LDH is released to the media
once cell membranes are damaged.
To determine in vivo specificity of produced CTLs, magnetically
labeled CTLs sensitized to U251 cells were intravenously injected
in mice bearing either subcutaneous MBA-MD-231 breast cancer
CTLs as Cellular MRI Probes
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of labeled CTLs all animals underwent in vivo MRI. On day 7 after
administration of cells animals were euthanized, perfused and
tumors along with surrounding tissues were collected for
histochemical analysis (Prussian blue staining).
U251 Glioma Rat Model
Following NIH guidelines under the institutional animal care
and user committee (IACUC) approved protocol, 48 nude rats
were inoculated intra-cerebrally as follows: Implantation: Animals
were anesthetized with 100 mg/kg of ketamine and 10 mg/kg of
xylazine i.p., the surgical zone was swabbed with betadine
solution, eyes coated with Lacri-lube and the animal was
immobilized in a small animal stereotactic device (Kopf, Cayunga,
CA). After draping, a 1-cm incision was made 2 mm to the right of
the midline and 1 mm retro-orbitally. The skull was exposed with
cotton-tip applicators and an HP-4 dental drill bit was used with a
micromanipulator to drill a hole 3 mm to the right of the bregma,
taking care not to penetrate the dura. A #2701 10 mL Hamilton
syringe with a #4 point, 26 gauge-needle containing tumor cells
(4610
5) was initially lowered to a depth of 3.5 mm, then raised
back up to a depth of 2.5 mm. The U251 cells were injected
stepwise at a rate of 0.5 mL/30 sec until the entire volume was
injected. During and after the injection, careful note was made of
any reflux from the injection site. After completing the injection,
the needle was withdrawn in a stepwise manner and the surgical
hole sealed with bone wax. Finally, the skull was swabbed with
betadine before suturing the skin over the injection site. Animals
were intravenously administered unlabeled CTLs, magnetically
labeled control T-cells or magnetically labeled CTLs on day 14
post-tumor implantation and MR images were obtained on days 3
and 7 after the administration of cells. There were two time points
(day 3 and 7 after injection) in each group (labeled control T-cells,
unlabeled CTLs and labeled CTLs). Results from a few rats were
discarded due to bleeding and failure to develop tumors, however
at least 5 animals were included at each time point for each group.
Radiation Injury to the Rat Brain
Animals (24 rats) were anesthetized using 100 mg/kg of
ketamine and 10 mg/kg of xylazine i.p. and restrained in a
stereotactic head holder. The site of irradiation was chosen to be at
3 mm right from bregma. Rats were irradiated sterotactically using
a single collimated dorso-ventral beam of 6MV X-rays with 1.5
mm thick bolus material placement so that 95–100% of the central
axis dose was delivered to the target volume [51]. The volume of
brain irradiated was a cylinder of radius 3 mm at the 80% isodose
boundary. The dose rate of 6 MV X-rays is 6 Gy/min using a 75-
cm source-to-skin surface distance. The radiation injury was
induced using 50Gy [52]. Based on our preliminary data and the
previous experiences (with radiation injuries which are obvious in
8 weeks), the animals were intravenously injected with either
unlabeled or labeled CTLs on day 56 after radiation exposure and
MR images were obtained on days 59 and 63. There were 6
animals studied at each time (59 and 63 days) point for each of 4
groups.
In Vivo MR Imaging Studies
An appropriate state of anesthesia was obtained with isoflurane
(3% for induction, 0.7% to 1.5% for maintenance in a 2:1 mixture
of N2:O2). The anesthetized rats were placed in a 7 Tesla, 20 cm
bore superconducting magnet (Magnex Scientific, Abingdon,
England) interfaced to a Bruker Avance console (Bellerica, MA).
A 12 cm self-shielded gradient set with maximum gradients of 25
gauss/cm was used. The radio frequency (rf) pulses were applied
by a 7.5 cm diameter saddle transmit coil actively decoupled from
the 3.2 cm diameter surface receive coil which was positioned over
the center line of the animal skull. Stereotaxic ear bars were used
to minimize movement during the imaging procedure. Rectal
temperature was maintained at 3760.5uC using a feedback
controlled water bath. After positioning using a triplanar FLASH
sequence, MR studies were performed using T2WI and T2*WI.
For detection of iron oxide labeled cells, scans typically employ
gradient-echo imaging methods to enhance T2*-weighting effects.
The following parameters were used to acquire MRI: T2 weighted
images (T2WI) were obtained using a standard two-dimensional
Fourier transformation (2DFT) multi-slice (13–15 slices) multi-
echo (6 echoes) MRI sequences with TEs of 15, 30, 45, 60, 75 and
90 msec and a TR of 3000 msec using a 32 mm FOV, 1 mm slice
thickness, 2566256 matrix, and NEX =2. The T2* weighted
images (T2*WI) were obtained using a standard multislice (13–15
slices) multi gradient-echo (4 echoes) MRI using TEs of 5, 10, 15,
and 20 msec and a TR of 3000 msec. The images were acquired
using a 32 mm FOV, 1 mm slice thickness, 2566256 matrix, and
NEX =2. We understand that post contrast T1WI will clearly
delineate the tumor margins as compared to T2WI. However, post
contrast T1WI relies on the BBB disruption or permeable tumor
vasculatures,that may not be present in the small number of cells
that migrate away from the typical tumor margin. These
microscopic satellite islands of tumors can not be delineated with
post-contrast T1WI because these tumor cells have co-opted
vessels and have not resulted in BBB disruption. On the other
hand, encircling all the high signal area on T2WI will include both
the tumor as well as surrounding edematous area that may contain
invasive tumor cells as well as the migrated CTLs.
Analysis of MRI Images
Transverse relaxation rate R2 (1/T2) and R2* (1/T2*) maps
were constructed from their respective multi-echo T2 and T2*
image sets. The T2 and T2* decay was estimated from a least
square fit on a pixel-by-pixel basis using an exponential model of
the time series extracted from the multi-echo T2-weighted spin-
echo and gradient-echo images, respectively. The Eigentool image
analysis software package, developed at the Radiology Image
Analysis Laboratory of the Henry Ford Hospital, Detroit, MI
(http://www.radiologyresearch.org/eigentool.htm) that includes
an implementation of this estimation algorithm was used. The
resultant values were inverted to generate the R2 and R2* maps.
The R2 and R2* values in the tumors or radiation injury and
contralateral brains were determined by hand drawn ROIs. The
R2 and R2* values were calculated from every section that
contained tumor. For radiation injury the ROIs were drawn for a
total of 5 sections of the brain (2 sections anterior to bregma, two
sections posterior to bregma and one at the site of bregma). The
R2 and R2* values in the tumors or radiation injury areas were
normalized to the corresponding contralateral brain by creating
the ratios of the tumor and radiation injury to the normal brain
(Tumor/Contralateral brain, Radiation injury/Contralateral
brain). The R2 and R2* values were determined by an operator
who was masked to the animal groups.
Histology and Immunohistochemistry
Animals were euthanized immediately after the last MR
imaging session to dissect the tissues via 150–200 mg/kg of
pentobarbital (administered by intravenous or intra-peritoneal
injection) and then perfused with 100 mL of saline and 100 ml of
3% paraformaldehyde for histological analysis. The whole brain
was collected and fixed in 4% paraformaldehyde and 3% sucrose.
The fixed brain was placed in a 200–400 g coronal rat-brain
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blocks. Blocks grossly containing and adjacent the tumor or
radiation injury were processed and paraffin embedded. Some of
the tissues were also processed as frozen sections. The embedded
blocks were cut into serial 10 mm sections for immunohistochem-
ical and Prussian blue staining. Consecutive tissue sections were
evaluated by the standard immunohistochemical techniques for
the presence of activated T-cells. Sections of the brain from both
the tumor and radiation injury areas were stained with Prussian
blue to determine the number of migrated iron positive cells at the
site of lesions.
Data Analysis
All data are expressed as mean 6 standard deviation (unless
indicated differently). Comparisons of measurements among the
tumor implanted groups and the radiation injury groups were
performed using repeated measurement analysis of variance
(ANOVA) followed by Fisher’s PLSD post hoc test. The p-values
equal to or less than 0.05 were considered significant.
Supporting Information
Table S1 Cell surface markers expression in CD14+ cells during
differentiation to mature dendritic cells in the presence of G-CSF
and IL-4 at different concentrations. In an attempt to optimize the
conditions for maturation of dendritic cells, after collection of
CD14+ cells by the magnetic cell sorting MACSH technique, cells
were incubated for 8 days in dendritic cell media containing
various relative and absolute amounts of G-CSF (granulocyte
colony stimulating factor) and IL-4 (interleukin 4), as shown in
Table 1. At the end of day 8 in culture, TNF-a at 100ng/ml was
added to the cells and incubated further for 3 days. Phenotypical
expression of different markers was determined at different time
points. There was no significant difference in the expression of
different markers among the different composition of cytokines.
We opted to use 50ng/ml of G-CSF, 25ng/ml of IL-4 and 100ng/
ml of TNF-a for all the subsequent experiments involving primed
mature dendritic cells. The data are expressed as mean 6 standard
deviation from sample sizes of 2 to 4. We have assessed HLA-DR
positive cells to determine monocyte-derived DCs.
Found at: doi:10.1371/journal.pone.0009365.s001 (0.04 MB
DOC)
Figure S1 MTT assay. MTT assay shows significantly
(p=,0.01) higher T-cell growth in the presence of primed
irradiated dendritic cells (PIDC).
Found at: doi:10.1371/journal.pone.0009365.s002 (1.77 MB TIF)
Figure S2 Labeling of CTLs. Commercially available, FDA-
approved SPIO, ferumoxides suspension, (Feridex IV H, Bayer-
Schering Pharmaceuticals Inc, Wayne, New Jersey) contains
particles approximately 80–150 nm in size and has a total iron
content of 11.2 mg/ml (11.2 of iron mg/ml). Protamine sulfate
(American Pharmaceuticals Partner Inc. Schaumburg, IL),
supplied at 10 mg/ml, was prepared as a fresh stock solution of
1 mg/ml in distilled water at the time of use. CTLs were collected
in tubes, washed two times with serum free media to get rid of the
serum and resuspended at the concentration of 46106 per ml of
serum free RPMI-1640 media containing L-glutamine, sodium
pyruvate and essential amino acids. Then 100 mg( 9ml of solution
from the bottle) of ferumoxides for each ml of cell suspension were
added to the tubes and mixed well. Three ml( 3mg of protamine
sulfate) of freshly prepared protamine sulfate was then added to
the tube containing cell suspension and ferumoxides, and mixed
well. The mixtures were transferred to 6-well plates at a
concentration of 106106 cell per well, i.e. 2.5 ml per well and
allowed to react for 15 minutes at 37uC in a tissue culture
incubator. After 15 minutes, equal volume of complete T-cell
media (RPMI1640, 10% FBS, 10 ng/ml IL-2, L-glutamine,
sodium pyruvate and essential amino acid) was added to the wells
and incubated for 4 hours. After incubation, cells were collected,
washed and cytospin slides were made. Prussian blue staining was
performed to determine the labeling efficiency. DAB enhanced
Prussian blue staining of unlabeled (A) and ferumoxides-protamine
sulfate labeled (B) CTLs. Note the extensive labeling of CTLs by
our newer procedure.
Found at: doi:10.1371/journal.pone.0009365.s003 (4.55 MB TIF)
Figure S3 Production and specificity of CTLs against U87 and
9L glioma. To determine whether the ex vivo method for priming
DC and sensitization of T-cells could be used to create CTLs
against U87 (human) and 9L (rat) glioma cell lines. U87 and 9L
tumor cell lysate primed mature DCs were produced using cord
blood derived CD14+ cells. These cells were then irradiated at
35Gy and co-cultured with cord blood derived CD2+/CD3+ cells
(T-cells) according to our described method. After 6 days of
sensitization, respective CTLs (200k) were added to wells
containing 9L and U87 cells. Same numbers of control T-cells
(200k, non-sensitized) were also added to the wells containing 9L
or U87 cells. Interaction (accumulation of added T-cells around
the U87 or 9L cells) of the added cells was photomicrographed at
18 hours. Left column: Morphology of 9L (upper panel) and U87
(lower panel) after incubation with 200k of CTCs (control T-cells)
at 18 hours. There is no change in the morphology of 9L and U87
cells, and CTCs (small round cells) appear to be passively
‘‘sitting’’on the tumor cells even after 18 hours of incubation.
Right column: Morphology of 9L (upper row) and U87 (lower
row) after incubation with 200k of respective CTLs (sensitized T-
cells) at 18 hours. Specific accumulations of CTLs around the
tumor cells are seen after 18 hours for both cell types. Compared
to the 9L and U87 cells cultured with CTCs (left column), there
are dramatic changes in the morphology of 9L and U87 cells
incubated with CTLs.
Found at: doi:10.1371/journal.pone.0009365.s004 (3.45 MB TIF)
Figure S4 In vivo specificity of CTLs. To determine in vivo
specificity of produced CTLs, magnetically labeled CTLs
sensitized to U251 cells were intravenously injected in mice
bearing either subcutaneous MBA-MD-231 breast cancer (n=2)
or U251 glioma (n-2) tumors. Three days following the
administration of labeled CTLs all animals underwent in vivo
MRI. Seven days after the administration of cells animals were
euthanized, perfused and tumors along with the surrounding
tissues were collected for histochemical analysis (Prussian blue
staining). Increased number of magnetically labeled CTLs were
observed in subcutaneous gliomas as compared to that of breast
cancers. The labeled CTLs accumulated not only at the periphery,
but also in the deeper parts of glioma tumors. Similar
accumulation was not observed in breast cancer tumors, which
indicates in vivo specificity of generated CTLs. Figure S4A:
Representative case of U251 tumor. Gradient echo (GRE) MRI
with two different echo times (TE), 10 ms (A) and 20 ms (B), shows
low signal intensity areas along the peripheral parts of the
subcutaneously implanted U-251 glioma (Arrows on A and B).
DAB enhanced Prussian blue staining shows numerous iron
positive cells (dark brown), not only in the peripheral parts (C, D,
arrows), but also in the deeper parts of the tumor (C, E, arrows).
(C) Two separate photomicrographs were combined together to
show the extent of accumulated iron positive cells (magnification
10x). D and E represent magnified images (magnification 25x) of
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231 tumor. Gradient echo (GRE) MRI with two different echo
times (TE), 10 ms (A) and 20 ms (B), shows no definite low signal
intensity areas along the peripheral parts of the subcutaneously
implanted MBA-MD-231 breast cancer tumor. However, large
low signal intensity areas were seen within the tumors (Arrows on
A and B), which are thought to be due to hemorrhage. DAB
enhanced Prussian blue staining shows no definite iron positive
cells at the peripheral parts (C, D) of the tumor, however, there are
multiple areas of hemorrhagic foci (RBC) seen in the deeper parts
of the tumor (E, arrows). A few iron positive cells, that could
possibly be injected CTLs, are seen in the deeper part of the tumor
(E, arrow head). (C) Magnification 10x. (D and E) Magnification
25x.
Found at: doi:10.1371/journal.pone.0009365.s005 (7.41 MB TIF)
Figure S5 Detection of smaller U251 tumor. Magnetically
labeled CTLs were injected intravenously in rats bearing U251
implanted tumor (n=3) on day 7 after the implantation. Both T2-
weighted (T2WI) and T2*-weighted (T2*WI) images were
acquired on day 3 and 7 after IV administration of CTLs.
Following the last MRI, animals were euthanized and their brains
including tumors were collected after perfusion and prepared for
histochemical analysis. Images from representative experiment
demonstrate migration and accumulation of administered CTLs in
the small tumor. Figure S5A: T2WI shows high signal intensity
areas (arrows) at the site that are considered to be the growing
tumor at day 10 (A) and day 14 (B) following the implantation of
tumor (day 3 and 7 after IV administration of labeled CTLs). Note
the extension of tumor along and below the corpus callosum.
T2*WI shows low signal intensity at the sites thought to be
growing tumor (arrows) at day 3 (C) and day 7 (D) after the
administration of labeled CTLs. Note the low signal areas that are
indeed within the high signal areas seen on T2WI. The low signal
area seen in the cortex (thick arrow) might be due to needle track
and hemorrhage during implantation of tumor. Figure S5B: DAB
enhanced Prussian blue (A, B) and CD45RO (C) staining from
consecutive sections showing the accumulated iron positive cells
(dark brown) in the small tumor mass (A, 10x) and (B, 40X).
CD45RO staining shows multiple activated T-cells within the
tumor (arrows, Magnification 40X).
Found at: doi:10.1371/journal.pone.0009365.s006 (9.53 MB TIF)
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